The State of Recovery Technology in 2026
Digital therapeutics survived Pear's bankruptcy. AI onboarding is here. Telehealth MAT is permanent. What works and what doesn't.
Body: [Draft covers: the digital therapeutic reset after Pear Therapeutics’ 2023 bankruptcy; the renaissance of behavioral health VC with mega-rounds (Talkiatry $210M, Grow Therapy $150M, Salma $80M); addiction-specific raises (Pelago $58M Series C, Boulder Care $35M, Quit Genius $14.7M); the investor shift toward outcomes and Medicaid populations; the permanent telehealth MAT rule as category tailwind; and what’s next — AI for relapse risk, personalized matching, crisis detection. Honest take: the space is maturing away from “wellness apps” toward accountable care.]
Related: Pelago, Boulder, Workit, Ophelia — who’s who in digital recovery | Pear Therapeutics bankruptcy — what the field learned | The permanent telehealth MAT rule, explained.
Sources Cited
- 01.Bhttps://rockhealth.com/insightsRock Health
- 02.Chttps://bhbusiness.comBehavioral Health Business
Filed Under
MAT — BuprenorphinePeer-Reviewed Research
Continue reading
More from this section
Relationship between attentional bias and psychological craving in methamphetamine use disorder
There's no FDA-approved medication for methamphetamine addiction. A dual-target TMS trial enrolling in 2026 targets the MPFC and DPFC simultaneously — the two brain regions most compromised by chronic stimulant use. Here's the science behind the approach.
Technology & InnovationAn AI Can Now Diagnose Addiction With 83% Accuracy. The Treatment System Still Can't Keep Up.
University of Cincinnati researchers built an AI that diagnoses substance use disorder with 83% accuracy using behavioral economics tools. The harder problem is what happens after the diagnosis.
Technology & InnovationOzempic for Addiction? The Science Is Catching Up to the Headlines
GLP-1 drugs like semaglutide show 50-56% lower AUD risk in a 2024 Nature study, with VA data confirming effects across 5+ substance classes. Clinical trials now running for opioid and cocaine use disorder.